Investigator's Brochure (IB) Table
Drugs
| Drug Name | Drug Company Sort descending | IB Date | Risk List Available? |
|---|---|---|---|
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Glecaprevir/Pibrentasvir - New - New | AbbVie | January 2024 | |
| Tenofovir | Conrad | November 2024 | |
| Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| Remdesivir (Veklury) | Gilead Sciences | June 2021 | |
| Pretomanid (PA-824) | Global Alliance for TB Drug Development (TB Alliance) | November 2023 | |
| TBI-223 | Global Alliance for TB Drug Development (TB Alliance) | October 2023 | |
| Sutezolid - New - New | Global Alliance for TB Drug Development (TB Alliance) | April 2025 | |
| Quercefit (Quercetin Phospholipid) - New - New | Indena | February 2025 | |
| Dapivirine (Vaginal Ring) | International Partnership For Microbicides | May 2024 | |
| Rilpivirine (TMC278, Edurant) | Janssen Research & Development | July 2024 | |
| Bedaquiline (TMC207) | Janssen Research & Development | October 2024 | |
| Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) | Merck | July 2021 | |
| Vorinostat (Zolinza) | Merck | August 2013 | |
| Delamanid (OPC-67683) | Otsuka | August 2024 | |
| Tecovirimat (TPOXX) | SIGA Technologies, Inc. | January 2025 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | October 2024 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | January 2025 |
Vaccines
| Vaccine Name | Vaccine Company | IB Date | Risk List Available? |
|---|---|---|---|
| DV700P-RNA and DV701B1.1-RNA - New - New | Duke Human Vaccine Institute (DHVI) | February 2025 | |
| Poly-ICLC (Hiltonol) | Oncovir, Inc. | January 2024 | |
| CD40.HIVRI.Env (VRIPRO) | Vaccine Research Institute (VRI) | November 2024 | |
| UVAX-1197 / UVAX-1107 | Uvax Bio LLC | January 2025 | |
| VIR-1778 | Vir Biotechnology | May 2024 | |
| HxB2.WT.Core-C4b, Adjuvanted | DAIDS/NIAID/NIH | October 2024 | |
| mRNA-1645-eODGT8 and mRNA-1645-CoreG28v2 | Moderna | October 2024 | |
| mRNA-1645-N332GT5 | Moderna | October 2024 | |
| 3M-052-AF | Access to Advanced Health Institute (AAHI) | November 2023 | |
| CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160 | Duke Human Vaccine Institute (DHVI) | November 2024 | |
| CD4BS CH505M5 Pr-NP1, Adjuvanted | DAIDS/NIAID/NIH | April 2024 | |
| BG505 SOSIP.GT1.1 gp140 Vaccine | International AIDS Vaccine Initiative (IAVI) | January 2024 | |
| 10-1074-LS(-J) | Rockefeller University/Celldex Therapeutics | November 2024 | |
| 3BNC117-LS (-J) | Rockefeller University/Celldex Therapeutics | November 2024 | |
| ID93 + GLA Adjuvant Vaccine | AAHI | March 2024 | |
| N332-GT5 gp140, Adjuvanted with SMNP | DAIDS/NIAID/NIH | July 2024 | |
| MTBVAC | Biofabri | July 2024 | |
| V3G CH848 Pr-NP1, Adjuvanted and V3G CH848 mRNA-Tr2 | VRC/NIAID/NIH | September 2024 | |
| HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL) | VRC/NIAID/NIH | July 2021 | |
| 16055 NFL Delta Gly4 Env Protein Trimer, Adjuvanted with 3M-052 AF + Alum | DAIDS/NIAID/NIH | December 2023 |